With the approval of MIPLYFFA, Zevra received a rare pediatric disease Priority Review Voucher (PRV) which the Company could monetize to help fund its growth. As of Oct. 31, Zevra has received 90 ...
Abeona may be eligible for a Priority Review Voucher (PRV) should pz-cel be approved. About prademagene zamikeracel (pz-cel) Prademagene zamikeracel (pz-cel), Abeona’s investigational autologous, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback